ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Hyaluronic Acid

Also written as “sodium hyaluronate 0.18%”, “Sodium hyaluronate” and “sodium hyaluronate”.

Its studies are mostly in Dry Eye Syndromes · Osteoarthritis, Knee · Osteoarthritis · Gingivitis · Keratoconjunctivitis Sicca, led by 10 companies.

Drug pageHyaluronic Acid: every studyMany companies study it; this page follows only the 17 they lead. All 195 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 7, 202117 company-led studies, 1 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Laboratorios Sophia S.A de C.V.its history only40 open or runningphase 4since Jan 7, 2021Sep 4, 2019none ahead
AbbVieits history only30 open or runningphase 4since Sep 25, 2008Sep 25, 2008none ahead
Sanofiits history only30 open or runningphase 4since Aug 12, 2005Aug 12, 2005none ahead
Daiichi Sankyo10 open or runningphase 3since May 23, 2006May 23, 2006none ahead
IBSA Institut Biochimiqueits history only11 open or runningphase 3since Sep 9, 2026Sep 9, 2026Jun 30, 2027phase 3 · NCT07819461
KLSMC Stem Cellsits history only10 open or runningphase 2since Mar 24, 2017Mar 24, 2017none ahead
Kunming Baker Norton Pharmaceutical Salesits history only10 open or runningphase 4since Jun 27, 2016Jun 27, 2016none ahead
Lantibioits history only10 open or runningphase 3since Jan 11, 2008Jan 11, 2008none ahead
Liquidia Technologiesits history only10 open or runningphase 1since Nov 22, 2016Nov 22, 2016none ahead
TRB Chemedicaits history only10 open or runningphase 2since Dec 23, 2010Dec 23, 2010none ahead

Also a collaborator on its studies: Premier Research Group and River Plate Biotechnology.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Daiichi Sankyo only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 23, 2006First study: phase 3 study in Osteoarthritis, HipFirst studyNCT00330135 · 85 enrolled · France

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Daiichi Sankyo leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00330135Osteoarthritis, Hip · France3TerminatedMar 200785

How it is read

Names in the registry

  • “sodium hyaluronate 0.18%”, 2 entries
  • “Sodium hyaluronate”, 2 entries
  • “sodium hyaluronate”, 2 entries
  • “Hyalgan (sodium hyaluronate)”, 2 entries
  • “Sodium hyaluronate solution - 3.36%”, 1 entry

Codes read as this program: PRO037.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.